Scarica l'app Stockscreener
2.40
2.56%
0.06
Pre-mercato:
2.45
0.05
+2.08%
Entera Bio Ltd Borsa (ENTX) Ultime notizie
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decrease in Short Interest - Defense World
Entera Bio files Exhibit 5.1 with SEC By Investing.com - Investing.com South Africa
Entera Bio files Exhibit 5.1 with SEC - Investing.com
Entera Bio (NASDAQ:ENTX) Stock Price Up 1.1% – Still a Buy? - Defense World
Entera Bio (NASDAQ:ENTX) Shares Up 1.1%Time to Buy? - MarketBeat
Hypoparathyroidism Market Overview, Trends, Insights, - openPR
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Simply Wall St
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Rises By 19.0% - MarketBeat
Knoll Capital Management, LLC's Strategic Acquisition in Entera Bio Ltd - GuruFocus.com
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update - MarketBeat
FY2024 EPS Estimate for Entera Bio Decreased by Analyst - MarketBeat
HC Wainwright Reaffirms Buy Rating for Entera Bio (NASDAQ:ENTX) - MarketBeat
Entera Bio Ltd. (ENTX) Quarterly 10-Q Report - Quartzy
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Entera Bio Highlights Q3 2024 Financials and FDA Anticipation - TipRanks
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - The Manila Times
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Drops By 14.4% - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 38.4% in September - MarketBeat
Entera Bio outlook steady as H.C. Wainwright backs potential of total hip BMD in osteoporosis care - Investing.com Australia
Entera Bio (NASDAQ:ENTX) Rating Reiterated by HC Wainwright - MarketBeat
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data - MSN
Entera Bio shares hold Buy rating on OXM study success By Investing.com - Investing.com Australia
Entera Bio shares hold Buy rating on OXM study success - Investing.com
Entera Bio's (ENTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com Australia
Entera Bio and OPKO Health report promising obesity treatment study - Investing.com
Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders - XM
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide - EIN News
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? - MSN
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? - MSN
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
Entera Bio to Participate in Upcoming Investor and Scientific Conferences - GlobeNewswire
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy - Yahoo Finance
Entera Bio Ltd. Forecasted to Earn Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:ENTX) - Defense World
Entera Bio Ltd. to Post Q3 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:ENTX) - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 51.0% in July - MarketBeat
Entera Bio (NASDAQ:ENTX) Releases Earnings Results - MarketBeat
Entera Bio's (ENTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Entera Bio (NASDAQ:ENTX) - Defense World
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - GlobeNewswire
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):